Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

• Status: Unknown status
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase II, monocentric, open label study to assess safety and activity of intralesional Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Andres J. M. Ferreri
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• histological diagnosis of CD20+ B cell lymphoma subtypes: marginal zone lymphoma, grade 1-2 follicular lymphoma, plasmocytic lymphoma, small lymphocyte lymphoma

• conjunctival localization alone (1EA stage; mono- or bilateral)

• at least one measurable lesion

• age >/= 18 years

• ECOG-PS
• HIV 1-2 negativity

• at least one previous treatment (antibiotic or rituximab)

Exclusion Criteria:

• concomitant conventional (chemo-, radiation, immuno-), experimental (antibiotic) or corticosteroid anticancer therapy

• known allergy to rituximab

• systemic symptoms

• concurrent diagnosis of pemphigus

• postsurgical conjunctival scars